Comparative analysis of potential drug-drug interactions at the level of public pharmacy

  • Sanja Stankovic Faculty of Medicine, Departement of Pharmacy, University of Nis
  • Nikola Stefanovic
  • Maša Jović
  • Radmila Veličković Radovanović Faculty of Medicine, Departement of Pharmacy, University of Nis
Keywords: types of interactions; comparison; databases; drug-drug

Abstract


Introduction: Understanding the mechanisms and classification of drug interactions can significantly reduce the occurrence of adverse effects and improve compliance. The drug selection process is complex and involves the patient's individual condition, physiological status, use of other drugs, and co-existing illnesses. It is particularly challenging to choose adequate therapy for elderly individuals due to physiological changes and polypharmacy.

Methods: A comparative analysis of potential drug-drug interactions was conducted on a sample of 215 outpatients. The analysis was performed using Lexicomp®, Medscape® and Epocrates® databases. The frequency of certain types of interactions by drug databases, the number of patients, and the distribution of interaction types by databases were determined. The frequency of drug combinations that could potentially cause serious and contraindicated interactions by databases were also determined.

Results: Based on the study, it can be concluded that there is a correlation between the number of prescribed drugs and potential interactions. According to frequency, the most common type of interaction requires therapy monitoring (type C interaction, Monitor). However, the same drug combinations have different classifications of interactions based on the severity categorization of available databases.

Conclusion: The obtained data can provide guidance in making decisions about drug therapy choices. Patient-specific characteristics, including comorbidities, require a personalized therapeutic approach from specialists, where pharmacists play a significant role.

References

1. Kheshti R, Aalipour M, Namazi S. A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. Journal of research in pharmacy practice. 2016; 5 (4): 257.
2. Kovačević Vezmar S, Miljković B. Klinička farmacija u teoriji i praksi. Pekografd.o.o. 2018; 56
3. Jain S, Jain P, Sharma K, Saraswat P. A prospective analysis of drug interactions in patients of intensive cardiac care unit. Journal of clinical and diagnostic research: JCDR. 2017; 11 (3): FC01
4. https://online.epocrates.com/drugs/121004/propafenone/Drug-Interactions
5. https://online.epocrates.com/drugs/105204/amlodipine/Drug-Interactions
6. Bačar Bole C, Nagode K, Pišlar M, Mrhar A, Grabnar I, Vovk T. Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders: Prevalence, Association with Risk Factors, and Replicate Analysis in 2021. Medicina. 2023; 59 (2): 284
7. Poznić-Ješić M, Ješić A, Babović-Filipović J, Živanović O. Extrapyramidal syndromes caused by antipsychotics. Medicinski pregled. 2012; 65 (11−12): 521−6.
8. Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS drugs. 2003; 17: 513−32.
9. Oh SW, Han SY. Loop diuretics in clinical practice. Electrolytes & Blood Pressure: E & BP. 2015 Jun;13(1):17.
10. Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction?. American Journal of Cardiovascular Drugs. 2003; 3: 149 −62.
11. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New England Journal of Medicine. 2001; 345 (25): 1809−17.
12. https://online.epocrates.com/interaction-check
13. Mandrioli R, Mercolini L, A Saracino M, A Raggi M. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Current medicinal chemistry. 2012; 19 (12): 1846−63.
14. Yang BR, Lee E, Hwang BS, Lee SH, Kang YJ, Jung SY. Risk of fracture in antidepressant users with concurrent use of benzodiazepines: A self-controlled case-series analysis. Bone. 2021; 153: 116109.
15. Farzam K, Tivakaran VS. QT prolonging drugs. InStatPearls [Internet] 2022 Jul 20. StatPearls Publishing.
16. Kokot F, Hyla-Klekot L. Drug-induced abnormalities of potassium metabolism. Pol Arch Med Wewn. 2008; 118 (7−8):431−4.
17. Letsas KP, Alexanian IP, Pappas LK, Kounas SP, Efremidis M, Sideris A, Kardaras F. QT interval prolongation and torsade de pointes associated with indapamide. International journal of cardiology. 2006; 112 (3): 373−4
Published
2025/11/20
Section
Originalni rad / Original article